Your browser doesn't support javascript.
loading
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
Van Cutsem, E; Yoshino, T; Lenz, H J; Lonardi, S; Falcone, A; Limón, M L; Saunders, M; Sobrero, A; Park, Y S; Ferreiro, R; Hong, Y S; Tomasek, J; Taniguchi, H; Ciardiello, F; Stoehr, J; Oum'Hamed, Z; Vlassak, S; Studeny, M; Argiles, G.
Afiliação
  • Van Cutsem E; Division of Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. Electronic address: eric.vancutsem@uzleuven.be.
  • Yoshino T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Lenz HJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA.
  • Lonardi S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua.
  • Falcone A; Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Limón ML; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain.
  • Saunders M; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Sobrero A; Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy.
  • Park YS; Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea.
  • Ferreiro R; Department of Clinical Oncology, Ramón y Cajal Hospital, Madrid, Spain.
  • Hong YS; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Tomasek J; Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Taniguchi H; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Ciardiello F; Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy.
  • Stoehr J; Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany.
  • Oum'Hamed Z; Boehringer Ingelheim France S.A.S, Reims, France.
  • Vlassak S; SCS Boehringer Ingelheim Comm.V, Brussels, Belgium.
  • Studeny M; Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria.
  • Argiles G; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
Ann Oncol ; 29(9): 1955-1963, 2018 09 01.
Article em En | MEDLINE | ID: mdl-30010751
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenocarcinoma / Inibidores de Proteínas Quinases / Indóis / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Adenocarcinoma / Inibidores de Proteínas Quinases / Indóis / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article